Data and Sample requests may be made through the following link: https://ais.swmed.edu/redcap/surveys/?s=CX8MJ4Y7XD
TARCC maintains a biorepository of blood specimens that correspond to annual visits of TARCC participants. These blood specimens include Serum, Plasma, whole blood, buffy coat, and DNA. In addition to the data points listed in the data variables spreadsheet, Genetic I and Genetics II data is also available for many of the TARCC participants, as follows:
Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA), which includes 906,600 single nucleotide polymorphism (SNP) and 946,000 copy number variation (CNV) markers. The new Affymetrix Genome-Wide Human SNP Array 6.0 features 1.8 million genetic markers, including more than 906,600 SNPs and more than 946,000 probes for the detection of CNV. The SNP Array 6.0 is the only platform with analysis tools to truly bridge copy number and association, including a new, high-resolution reference map and a copy number polymorphism calling algorithm developed by the Broad Institute.
Illumina Multi-Ethnic Global Array (MEGA) (Illumina, San Diego, CA), which includes 2,036,060 SNP markers. The Expanded Multi-Ethnic Genotyping Array (MEGAEX) leverages content from Phase 3 of the 1000 Genomes Project (1kGP)1, Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA), Population Architecture using Genomics and Epidemiology (PAGE), T2D-Genes Consortium, OMIM, ClinVar, ACGM, carrier screening panels, and other resources to create a true multipurpose, multiethnic array.
If you would like any specific information about available genetics data, how many subjects we have with a certain diagnosis, or answered a question a certain way, or some other feasibility issue before you submit a full application, please email [email protected]. Our database administrator will help you with this information. For any other questions please also contact [email protected].
When using this data set, to ensure proper acknowledgement is given to the state of Texas and to the Texas Council on Alzheimer’s disease and Related Disorders, the following Statement of Acknowledgement must be included in all publications, printed materials and deliverables:
"This study was made possible (*in part if necessary) by the Texas Alzheimer’s Research and Care Consortium (TARCC) funded by the state of Texas through the Texas Council on Alzheimer’s Disease and Related Disorders.”
Recently Approved Projects Requesting Data and/or Samples
The Association Between Sociodemographic Characteristics and Disparities in Clinical Characterization for Dementia Diagnosis
Andrea Ochoa, BS
University of Houston
Systemic Inflammation in AD Patients
Laurent Calvier, PhD
UT Southwestern
Predictors of Disparities in Neurocognitive Aging
Archana McEligot, PhD, MS
California State University, Fullerton
Comparison of Neuropsychological testing scores in Mild Traumatic Brain Injuries paralleled with no report of a Traumatic Brain Injury History
Christian Lobue, PhD
UT Southwestern
Sex hormones and the incident of mild cognitive impairment and Alzheimer ’s disease
Alok Dwivedi, PhD
Texas Tech University Health Science Center, El Paso
Alzheimer's disease sequencing project phenotype harmonization consortium (ADSP-PHC)
Timothy Hohman, PhD
Vanderbilt University Medical Center
GWAS of AD/ADRD and related endophenotypes in the TARCC research cohort
Xueqiu Jian, PhD
UT Health San Antonio
Role of brain derived exosomes in the progression of Alzheimer's disease
Michela Marcatti, PhD
University of Texas Medical Branch at Galveston
Ancestry-specific effects of APOE on AD phenotypes and risk factors
Shea Andrews, PhD
University of California, San Francisco
Heterogeneity of APOE e4 induced Alzheimer’s disease risk across Hispanic ethnicities
Robert Barber, PhD
University of North Texas Health Science Center
Characterizing exosome contribution to the development of Alzheimer’s disease pathology
Benjamin Landon, BS (Doctoral Student)
University of North Texas Health Science Center
tRNA-Derived Fragments (tRFs) as potential biomarkers for Alzheimer's disease
Xiaoyong Bao, PhD
UT Medical Branch at Galveston
Genetic risk for trajectories of cognitive decline and progression to dementia
Xueqiu Jian, PhD
UT Health San Antonio
Using Machine Learning to Predict Alzheimer's Risk
John Broussard, PhD
UT Health Houston
Aldehyde dehydrogenase 2 polymorphism in Alzheimer's disease
Jessy Etienne, PhD
Stanford
Identifying biomarkers in Alzheimer's Clinical Syndrome associated with prior head trauma
Christian Lobue, PhD
UT Southwestern
Inflammation Biomarkers and Neuropsychological Performance in Alzheimer's disease
Moriah Splonskowski, MS
Pacific University
Infection-driven mechanisms associated with Alzheimer’s disease pathology
Tatiana Barichello, PhD
UT Health Houston
Assessing sex differences in gut metabolites in AD/MCI patients
Farida Sohrabji, PhD
Texas A&M University Health Science Center
Evaluation and development of methods for multi-cohort association studies with diverse covariates
Arif Harmanci, PhD
UT Health Houston
Studying the effect of APOE genotype on cognitive networks in a large multi-ethnic cohort of healthy adults and neurodegenerative patients
Matteo De Marco, PhD
Brunel University London
Examining plasma-based AD biomarkers across assay platforms
Sid O’Bryant, PhD
University of North Texas Health Science Center
An investigation of drug effects on cognition and/or Alzheimer’s disease biomarkers in the elderly
Anton Gietl, MD
University of Zurich
Characterization of a New Risk Cell Type in Alzheimer's Disease
Lu Sun, PhD
UT Southwestern
Monitoring plasma contact system activation in the progression of Alzheimer’s disease
Erin Norris, PhD
Rockefeller University
Detection of oligomeric beta-amyloid in Alzheimer’s disease using a diphenylalanine-specific probe
Tianfu Wu, PhD
University of Houston
Cognitive function, diabetes, and neuropsychiatric symptoms in Mexican Americans: A secondary analysis of the Texas Alzheimer’s Research and Care Consortium
Heather Cuevas, PhD, RN
University of Texas at Austin School of Nursing
Exploring the neurocognitive links in Alzheimer’s disease: A network study
Adam Calderon, MA
Columbia University and the Fulbright Program at the Hungarian Academy of Sciences
Comparing serum-based biomarkers associated with AD across technological platforms
Sid O’Bryant, PhD
University of North Texas Health Science Center
The genetic basis of Alzheimer disease in Hispanic Americans affected by type-2 diabetes
Upal Roy, PhD
UT Health Rio Grande Valley
Blood Biomarker for Alzheimer's Disease & Disease Progression: Phospholipids
Dwight German, PhD
UT Southwestern
Neuropsychological predictors of time to conversion from mild cognitive impairment to Alzheimer's disease
Allison Parker
UT Southwestern
Predictive utility of cognitive intraindividual variability in the TARCC cohort
Bonnie M. Scott, PhD
UT Austin Dell Medical School
Dynamic modeling, prediction and identification of significant prognostic factors of Alzheimer's disease
Liang Zhu, PhD
UT Health Houston
Cracking the Latino paradox: The role of social isolation as a predictor of cognitive performance in Hispanics
Mirna Luz Arroyo-Miranda, JD, DrPH
University of Houston
Assessing sex differences in gut metabolites in AD/MCI patients
Farida Sohrabji, PhD
Texas A&M University Health Science Center
Role of indoles in delaying the onset of Alzheimer's disease
Xiang Fang, MD, PhD, FAAN, FANA
UT Medical Branch at Galveston
An initial study of health aging and Alzheimer's disease (AD) among Hispanic population: interactions of lifestyle and genes
Chun Zu, MD, PhD, MSc
UT Health Rio Grande Valley
Inflammatory phenotype associated with the uniquely human gene CHRFAM7A in blood-based biomarkers
Kinga Szigeti, MD, PhD
University at Buffalo
Investigating the role of inflammation on apathy in Alzheimer's disease
Antonio Teixeira, MD, PhD, MSc
UT Health Houston
Latent class modelling of a diverse clinical sample: Identification of unique trends and patterns of performance in neuropsychological measures
William Goette
UT Southwestern
Genetics of Alzheimer's disease across the spectrum of ancestry, age, sex, and APOE4
Michael Belloy, PhD
Stanford University
Addressing model misspecification to profile Alzheimer patient subgroups for precise clinical trials
Tanya Garcia, PhD
Texas A&M University
Reinforcement learning for medication and diagnosis of Alzheimer's disease
Yejin Kim, PhD
UT Health Houston
Adaptation and application of an actuarial neuropsychological diagnostic algorithm to the Texas Alzheimer's Research and Care Consortium's database
William Goette
UT Southwestern
The relationship between the cognitive impairment, neuropsychiatric disturbances and activities in daily living in patients with MCI and Alzheimer's disease
Parunyou Julayanont, MD
Texas Tech University Health Science Center
Detection of Aldolase A in human clinical samples towards early detection of Alzheimer’s disease progression
Balaji Krishnan, PhD
UT Medical Branch at Galveston